These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 28315136

  • 1. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
    Fujita K, Iguchi Y, Une M, Watanabe S.
    Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Consumption of soy protein isolate reduces hepatic SREBP-1c and lipogenic gene expression in wild-type mice, but not in FXR-deficient mice.
    Hashidume T, Sasaki T, Inoue J, Sato R.
    Biosci Biotechnol Biochem; 2011 Apr; 75(9):1702-7. PubMed ID: 21897047
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    Panzitt K, Jungwirth E, Krones E, Lee JM, Pollheimer M, Thallinger GG, Kolb-Lenz D, Xiao R, Thorell A, Trauner M, Fickert P, Marschall HU, Moore DD, Wagner M.
    J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
    [Abstract] [Full Text] [Related]

  • 12. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y, LaCerte C, Kansra S, Jackson JP, Brouwer KR, Edwards JE.
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [Abstract] [Full Text] [Related]

  • 13. Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.
    Watanabe S, Fujita K.
    Lipids; 2014 Oct; 49(10):963-73. PubMed ID: 25189147
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bile acid nuclear receptor FXR and digestive system diseases.
    Ding L, Yang L, Wang Z, Huang W.
    Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
    [Abstract] [Full Text] [Related]

  • 16. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model.
    Taylor R, Yang Z, Henry Z, Capece G, Meadows V, Otersen K, Basaly V, Bhattacharya A, Mera S, Zhou P, Joseph L, Yang I, Brinker A, Buckley B, Kong B, Guo GL.
    Toxicol Sci; 2024 May 28; 199(2):316-331. PubMed ID: 38526215
    [Abstract] [Full Text] [Related]

  • 17. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
    Hu X, Bonde Y, Eggertsen G, Rudling M.
    J Intern Med; 2014 Jan 28; 275(1):27-38. PubMed ID: 24118394
    [Abstract] [Full Text] [Related]

  • 18. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
    Li X, Yuan Z, Liu R, Hassan HM, Yang H, Sun R, Zhang L, Jiang Z.
    Toxicol Appl Pharmacol; 2016 Nov 15; 311():12-25. PubMed ID: 27743861
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
    Yu DD, Andrali SS, Li H, Lin M, Huang W, Forman BM.
    Bioorg Med Chem; 2016 Sep 15; 24(18):3986-3993. PubMed ID: 27372840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.